Overview of Dr. Francis
Dr. Jasmine Francis is an ophthalmologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from New York University Grossman School of Medicine and has been in practice 10 years. She is one of 19 doctors at Memorial Sloan Kettering Cancer Center who specialize in Ophthalmology. She has more than 100 publications and over 500 citings.
Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021- Is this information wrong?
Education & Training
Icahn School of Medicine at Mount Sinai/New York Eye and Ear Infirmary at Mount SinaiResidency, Ophthalmology, 2008 - 2011
New York University School of MedicineClass of 2007
Certifications & Licensure
NY State Medical License 2008 - 2024- American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors.Jasmine H Francis, Christopher A Barker, Julia Canestraro, David H Abramson, Alexander N Shoushtari> ;American Journal of Ophthalmology Case Reports. 2024 Jun 1
- Circulating Tumor DNA Posttreatment Measurements and Clinical Correlates in Retinoblastoma.David H Abramson, Melissa A Robbins, Y Pierre Gobin, Ira J Dunkel, Jasmine H Francis> ;JAMA Ophthalmology. 2024 Mar 1
- Ocular toxicities of fibroblast growth factor receptor inhibitors: A review.Jerry Hsu, Jasmine H Francis, Sumayya Ahmad> ;Survey of Ophthalmology. 2023 Sep 28
- Join now to see all
Journal Articles
- Growth Patterns of Survivors of Retinoblastoma Treated with Ophthalmic Artery ChemosurgeryJasmine H Francis, Y Pierre Gobin, David H Abramson, PLoS One
- Total Retinal Detachments Due to Retinoblastoma: Outcomes Following Intra-Arterial chemotherapy/ophthalmic Artery ChemosurgeryIra J Dunkel, Jasmine H Francis, Y Pierre Gobin, Scott E Brodie, David H Abramson, PLoS One
- Clinical and Morphologic Characteristics of MEK Inhibitor–Associated RetinopathyJasmine Francis, MD, Ophthalmology
Press Mentions
FDA Approves First Treatment for Patients with All Forms of HistiocytosisJanuary 30th, 2023- Doctors Identify an Eye Cancer CulpritSeptember 13th, 2021
Twenty-Year Collaboration Between North American and South American Retinoblastoma ProgramsMarch 30th, 2020
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
